Aquestive Therapeutics reported second quarter 2026 financial results, posting total revenues of $13.8 million compared to $10.0 million in the prior year period. The company recorded a net loss of $22.9 million, or $0.18 per share, driven largely by an $11.7 million one-time loss on the extinguishment of its 13.5% Notes. Excluding this non-cash charge, the adjusted net loss was $11.2 million. The firm completed required human factors and pharmacokinetic studies for Anaphylm, reaffirming plans to resubmit the New Drug Application to the FDA in Q3 2026. Cash and cash equivalents stood at $98.5 million as of June 30, 2026. Aquestive Therapeutics operates in the pharmaceutical industry, developing proprietary drug delivery technologies and manufacturing products for licensees.
